GlassScriptPhysician profile
Yefim Levy
NPI 1063580413
$380.58
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.89 · 2020: $14.32 · 2021: $162 · 2022: $123 · 2023: $37.52 · 2024: $19.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $65.59 | 2021-2022 | |
| Allergan, INC. | $49.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $38.35 | 2020-2022 | |
| Galt Pharmaceuticals, LLC | $37.52 | 2023 | Orphengesic Forte |
| Jazz Pharmaceuticals INC. | $37.14 | 2022 | |
| Amarin Pharma, INC. | $23.89 | 2019 | |
| Biocryst US Sales Co., LLC | $21.56 | 2022 | |
| Novo Nordisk INC | $20.84 | 2021 | |
| Leo Pharma INC. | $20.40 | 2021 | |
| Lilly USA, LLC | $19.08 | 2024 | Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $17.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.92 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yefim Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.